• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFR14A filed by Processa Pharmaceuticals Inc.

    6/11/24 2:19:42 PM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PCSA alert in real time by email
    DEFR14A 1 formdefr14a.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

    PROXY STATEMENT PURSUANT TO SECTION 14(a)

    OF THE SECURITIES EXCHANGE ACT OF 1934

     

    Filed by the Registrant ☒

     

    Filed by a Party other than the Registrant ☐

     

    Check the appropriate box:

     

    ☐ Preliminary Proxy Statement
       
    ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
       
    ☐ Definitive Proxy Statement
       
    ☒ Definitive Additional Materials
       
    ☐ Soliciting Materials Pursuant to §240.14a-12

     

    Processa Pharmaceuticals, Inc.

    (Name of Registrant as Specified in Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):
     
    ☒ No fee required.
    ☐ Fee paid previously with preliminary materials.
    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Rules 14a-6(i)(1) and 0-11.

     

     

     

     

     

     

     

    7380 Coca Cola Drive, Suite 106

    Hanover, MD 21076

     

    ANNUAL MEETING OF STOCKHOLDERS TO BE HELD JUNE 28, 2024

     

    Supplement No. 1 to

    Definitive Proxy Statement dated April 29, 2024

     

    On April 29, 2024, Processa Pharmaceuticals, Inc. (the “Company”) filed a definitive proxy statement (the “Proxy Statement”) with the Securities and Exchange Commission, which was distributed in connection with the Company’s Annual Meeting of Stockholders to be held on June 28, 2024. The Company is providing this supplement solely to provide the Pay Versus Performance Table and related disclosures:

     

    Pay Versus Performance Table

     

    In accordance with rules adopted by the Securities and Exchange Commission (“SEC”), we are providing the following disclosure regarding executive “compensation actually paid,” presented in a manner consistent with the rules applicable to smaller reporting companies. The amounts in the table below are calculated in accordance with SEC rules and do not represent amounts actually earned or realized by our named executive officers (“NEOs”).

     

    Year  Summary Compensation Table Total for PEO (David Young) ($) (a)   Compensation Actually Paid to PEO (David Young) ($) (b)   Summary Compensation Table Total for PEO (George Ng) ($) (a)   Compensation Actually Paid to PEO (George Ng) ($) (b)   Average Summary Compensation Table Total for Non-PEO NEOs ($) (c)   Average Compensation Actually Paid to Non-PEO NEOs ($) (d)   Value of Initial Fixed $100 Investment Based on the Total Shareholder Return of the Company ($) (e)   Net Income (Loss) ($ in millions) (f) 
    2023   108,876    (16,297)   472,849    428,849    306,661    13,318    5    (11,122)
    2022   1,162,619    549,308    N/A    N/A    1,044,174    424,104    17    (27,474)
    2021   434,512    342,274    N/A    N/A    498,417    396,458    74    (11,427)

     

    (a)The principal executive officer (“PEO”) is David Young during 2021, 2022 and from January 1, 2023 through August 8, 2023. George Ng joined the Company on August 8, 2023.
      
    (b)Compensation actually paid (“CAP”) reflect the adjustments listed in the tables below to the amounts reported in the Summary Compensation Table for PEOs:

     

    David Young:

     

    Year  2021   2022   2023 
    SCT Total Compensation ($)   434,512    1,162,619    108,876 
    Less: Stock and Option Award Values Reported in SCT for the Covered Year ($)   (347,012)   (1,068,744)   (15,426)
    Plus: Fair Value for Stock and Option Awards Granted in the Covered Year that are Outstanding and Unvested at End of Year ($)   84,182    272,646    4,698 
    Change in Fair Value of Outstanding Unvested Stock and Option Awards from Prior Years ($)   (13,183)   (32,680)   (1,919)
    Fair Value as of Vesting Date for Awards Granted that Vested in Same Year ($)   196,923    249,153    - 
    Change in Fair Value of Stock and Option Awards from Prior years that Vested in the Covered Year ($)   (13,148)   (28,956)   (112,526)
    Less: Fair Value of Stock and Option Awards Forfeited during the covered Year ($)   -    (4,730)   - 
    Less: Aggregate Change in Actuarial Present Value of Accumulated Benefit Under Pension Plans ($)   -    -    - 
    Plus: Aggregate Service Cost and Prior Service Cost for Pension Plans ($)   -    -    - 
    Compensation Actually Paid ($)   342,274    549,308    (16,297)

     

     

     

     

    George Ng:

     

    Year  2023 
    SCT Total Compensation ($)   472,849 
    Less: Stock and Option Award Values Reported in SCT for the Covered Year ($)   (312,000)
    Plus: Fair Value for Stock and Option Awards Granted in the Covered Year that are Outstanding and Unvested at End of Year ($)   268,000 
    Change in Fair Value of Outstanding Unvested Stock and Option Awards from Prior Years ($)   - 
    Fair Value as of Vesting Date for Awards Granted that Vested in Same Year ($)   - 
    Change in Fair Value of Stock and Option Awards from Prior years that Vested in the Covered Year ($)   - 
    Less: Fair Value of Stock and Option Awards Forfeited during the covered Year ($)   - 
    Less: Aggregate Change in Actuarial Present Value of Accumulated Benefit Under Pension Plans ($)   - 
    Plus: Aggregate Service Cost and Prior Service Cost for Pension Plans ($)   - 
    Compensation Actually Paid ($)   428,849 

     

    (c)The following are included in the average figures shown:

     

    2021: Sian Bigora, Michael Floyd, Wendy Guy, Patrick Lin and James Stanker

    2022: Sian Bigora, Michael Floyd, Wendy Guy, Patrick Lin and James Stanker

    2023: David Young (from August 8, 2023 – December 31, 2023), Sian Bigora and James Stanker

     

    (d)Compensation actually paid (CAP) to our non-PEO NEOs reflects the respective amounts set forth in column (d) of the table above, adjusted as set forth in the table below. The assumptions used to calculate the fair values did not differ materially from the assumptions used to calculate the fair values as of the grant dates.

     

    Year  2021   2022   2023 
    Non-PEO NEOs   See column (c) note above    See column (c) note above    See column (c) note above 
    SCT Total Compensation ($)   498,417    1,044,174    306,661 
    Less: Stock and Option Award Values Reported in SCT for the Covered Year ($)   (347,443)   (935,747)   (136,489)
    Plus: Fair Value for Stock and Option Awards Granted in the Covered Year ($)   84,182    272,646    41,567 
    Change in Fair Value of Outstanding Unvested Stock and Option Awards from Prior Years ($)   (14,348)   (32,650)   (3,285)
    Fair Value as of Vesting Date for Awards Granted that Vested in Same Year ($)   196,923    133,847    - 
    Change in Fair Value of Stock and Option Awards from Prior years that Vested in the Covered Year ($)   (21,273)   (53,436)   (194,736)
    Less: Fair Value of Stock and Option Awards Forfeited during the covered Year ($)   -    (4,730)   - 
    Less: Aggregate Change in Actuarial Present Value of Accumulated Benefit Under Pension Plans ($)   -    -    - 
    Plus: Aggregate Service Cost and Prior Service Cost for Pension Plans ($)   -    -    - 
    Compensation Actually Paid ($)   396,458    424,104    13,718 

     

    (e) Total shareholder return is determined based on the value of an initial fixed investment of $100 in our common stock as of January 1, 2021.

     

    (f)Reflects “Net Income” in the company’s audited financial statement included in our Annual Reports on Form 10-K for each of the years ended December 31, 2021, 2022 and 2023.

     

     
     

     

    Pay Versus Performance Descriptive Disclosure

     

    Below are graphs showing the relationship of “compensation actually paid” to our PEOs and non-PEO NEOs in 2021, 2022 and 2023 to (1) our TSR and (2) our net income.

     

     

    This information should be considered part of the Company’s proxy materials. A notice of our meeting and how to vote your shares is provided below for your convenience.

     

     

     

     

     

     

     

     

     

     

     

    Get the next $PCSA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PCSA

    DatePrice TargetRatingAnalyst
    4/25/2024$8.00Buy
    H.C. Wainwright
    8/3/2021$20.00Outperform
    Oppenheimer
    8/2/2021$20.00Outperform
    Oppenheimer
    More analyst ratings

    $PCSA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference

    VERO BEACH, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, today announced that George Ng, Chief Executive Officer, and Patrick Lin, Chief Business & Strategy Officer and Founder, will attend the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12-15, 2026, in San Francisco, California. During the conference, Mr. Ng and Mr. Lin will be available for one-on-one meetings with investors and potential partners to discuss Processa's clinical pipeline, including the ongoing Phase 2 study evaluating NGC-Cap in patients with advanced or metastatic

    1/12/26 9:15:00 AM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study

    Interim safety and efficacy data to be reported in Q1 VERO BEACH, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, today reported that it completed the enrollment and dosing of the 20 patients required for the planned formal interim analysis in its ongoing Phase 2 clinical study evaluating NGC-Cap, Processa's proprietary combination treatment of PCS6422 and capecitabine, in patients with advanced or metastatic breast cancer. "This is an important milestone because it allows us to assess whether NGC-Cap can demonstrate a meaningful improvement over capecitabin

    1/5/26 9:15:00 AM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer

    Preliminary Phase 2 data demonstrate PCS6422+Capecitabine increased cancer-killing metabolite exposure while maintaining comparable safety to monotherapy capecitabine Company on track to conduct formal interim analysis in early 2026 VERO BEACH, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, today provided a clinical update on its ongoing Phase 2 study of NGC-Cap, the combination treatment of PCS6422 and capecitabine, in patients with advanced or metastatic breast cancer. Data from the first 16 of 19 patients enrolled indicate that NGC-Cap significantly inc

    12/17/25 8:00:00 AM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCSA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on AirGate PCS with a new price target

    H.C. Wainwright initiated coverage of AirGate PCS with a rating of Buy and set a new price target of $8.00

    4/25/24 6:22:04 AM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Processa Pharmaceuticals with a new price target

    Oppenheimer initiated coverage of Processa Pharmaceuticals with a rating of Outperform and set a new price target of $20.00

    8/3/21 4:49:09 AM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Processa Pharmaceuticals with a new price target

    Oppenheimer initiated coverage of Processa Pharmaceuticals with a rating of Outperform and set a new price target of $20.00

    8/2/21 4:20:20 PM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCSA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Pres. Research & Development Young David converted options into 49 shares, increasing direct ownership by 0.56% to 8,752 units (SEC Form 4)

    4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)

    2/4/26 5:09:36 PM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Business - Strategy Off Lin Patrick converted options into 193 shares, increasing direct ownership by 12% to 1,753 units (SEC Form 4)

    4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)

    2/4/26 5:07:34 PM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Administrative Officer Guy Wendy converted options into 193 shares, increasing direct ownership by 18% to 1,256 units (SEC Form 4)

    4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)

    2/4/26 5:05:30 PM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCSA
    SEC Filings

    View All

    Processa Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Processa Pharmaceuticals, Inc. (0001533743) (Filer)

    1/7/26 8:30:50 AM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Processa Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - Processa Pharmaceuticals, Inc. (0001533743) (Filer)

    12/15/25 11:00:32 AM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Processa Pharmaceuticals Inc.

    10-Q - Processa Pharmaceuticals, Inc. (0001533743) (Filer)

    11/6/25 4:07:39 PM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCSA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Yorke Justin W bought $9,889 worth of shares (12,400 units at $0.80) (SEC Form 4)

    4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)

    1/31/25 5:06:27 PM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Ng George K bought $69,542 worth of shares (87,200 units at $0.80) (SEC Form 4)

    4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)

    1/29/25 5:05:00 PM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pres. Research & Development Young David bought $99,289 worth of shares (124,500 units at $0.80), increasing direct ownership by 154% to 205,405 units (SEC Form 4)

    4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)

    1/29/25 4:24:39 PM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCSA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Processa Pharmaceuticals, Inc. (Amendment)

    SC 13G/A - Processa Pharmaceuticals, Inc. (0001533743) (Subject)

    8/10/21 5:02:22 PM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Processa Pharmaceuticals, Inc.

    SC 13G - Processa Pharmaceuticals, Inc. (0001533743) (Subject)

    6/11/21 1:11:49 PM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Processa Pharmaceuticals, Inc. (Amendment)

    SC 13G/A - Processa Pharmaceuticals, Inc. (0001533743) (Subject)

    4/8/21 5:15:23 PM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCSA
    Leadership Updates

    Live Leadership Updates

    View All

    Processa Pharmaceuticals Names Russell L. Skibsted as Chief Financial Officer

    HANOVER, Md., July 17, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, announces the appointment of Russell L. Skibsted as Chief Financial Officer (CFO), effective immediately. Mr. Skibsted succeeds James Stanker, who is retiring and staying on in an advisory role to assist in the transition. "We are delighted to welcome Russell to Processa's executive team. His proven record in finance and capital markets combined with a deep understanding of the complexities inherent in the life sciences make him a

    7/17/24 8:00:00 AM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer

    FDA and Processa agree to expand NGC-Cap development into breast cancer providing a more efficient path to approval FDA agrees that existing data and studies can be used to support the Phase 2 breast cancer trial design HANOVER, MD, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) ("Processa" or the "Company"), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering from cancer, announces it plans to expand the development of Next Generation Capecitabine ("NGC-Cap") into the treatment of advanced or metastatic breast cancer beginning with its ne

    1/19/24 7:45:00 AM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer

    HANOVER, MD, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) ("Processa" or the "Company"), a clinical-stage pharmaceutical company focusing on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces today that industry veteran George Ng has been appointed to serve as the Company's Chief Executive Officer and as a Board Director as of August 8, 2023. Dr. David Young will focus his efforts on the development of the Next Generation Chemotherapy (NGC) drugs as President of Research and Development and as a board member. "We are thrilled to have George assume the leadership of ou

    8/8/23 8:15:00 AM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCSA
    Financials

    Live finance-specific insights

    View All

    Processa Pharmaceuticals Reports Third Quarter Business Highlights and Financial Results

    First patient dosed in Phase 2 clinical trial with NGC-Cap for metastatic breast cancer Positive data from preclinical studies support NGC-Iri's ability to deliver more SN-38 to tumors compared with either irinotecan or Onivyde® HANOVER, Md., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, provides updates on its product pipeline, upcoming milestones and business activities, and reports financial results for the three and nine months ended September 30, 2024. "We continued to make progres

    10/30/24 4:15:00 PM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Processa Pharmaceuticals Provides Product Pipeline and Financial Update

    Phase 2 trial with NGC-Cap in breast cancer underway NGC-Cap Phase 1b trial demonstrated a favorable safety profile with preliminary anti-tumor activity Preclinical studies demonstrated NGC-Iri delivers more cancer-killing SN-38 molecules to tumor than either irinotecan or Onivyde® HANOVER, Md., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, provides updates on its product pipeline, upcoming milestones and business activities, and reports financial results for the three and six mont

    8/28/24 8:00:00 AM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Processa Pharmaceuticals to Host Conference Call to Discuss 2022 Year End Results and Provide Drug Development Update on March 30, 2023 at 4:30 p.m. EST

    HANOVER, MD, March 23, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) ("Processa" or the "Company"), a developer of Next Generation Chemotherapy drugs that provide a better safety-efficacy profile than their widely used FDA-approved counterparts, today announced that it will host a conference call and live webcast on March 30, 2023 at 4:30 p.m. EST to discuss its 2022 results and provide an update on its clinical pipeline for 2023. Conference Call Information To participate in this event, please log-on or dial-in approximately 5 to 10 minutes before the beginning of the call. Date: March 30, 2023Time: 4:30 p.m. ETToll Free: 888-506-0062Internatio

    3/23/23 8:30:00 AM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care